ERK1/2 [p Thr202, p Thr185] Antibody (E337)

Produced using Abcam's RabMab® technology. RabMab® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

Extra cellular signal-regulated kinases Erk1 (p44 MAPK) and Erk2 (p42 MAPK) Serine/Threonine proteine kinase are part of a subfamily of mitogen-activated protein kinases that participate in diverse cellular functions, including the regulation of cell growth, differentiation, apoptosis and signal transduction (1,2,3) The simultaneous tyrosine/threonine phosphorylation of ERK1 and ERK2 results in their activation. Although ERK1and ERK2 resemble one another closely in sequence and are activated by similar pathways, they appearto have different tissue distributions(4) and show differential phosphorylation of potential intracellular substrates(5)

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Showing Publications 1 - 2 of 2.

Publications using NB110-56969	Applications	Species
Iino K, Oki Y, Yamashita M et al. Possible relevance between prohormone convertase 2 expression and tumor growth in human adrenocorticotropin-producing pituitary adenoma. J Clin Endocrinol Metab 2010-08-01 [PMID: 20501680]
Koleganova N, Piecha G, Ritz E et al. Calcitriol ameliorates capillary deficit fibrosis of the heart in subtotally nephrectomized rats. Nephrol Dial Transplant 2008-01-01 [PMID: 18829613]

Array NB110-56969

• ERK1/2 Antibodies